Inovio Pharmaceuticals (INO) Competitors $1.41 -0.03 (-2.08%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.40 0.00 (-0.35%) As of 08/8/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INO vs. MRNA, CVRX, SKIN, MGRM, CV, SGHT, INGN, PROF, KRMD, and TLSIShould you be buying Inovio Pharmaceuticals stock or one of its competitors? The main competitors of Inovio Pharmaceuticals include Moderna (MRNA), CVRx (CVRX), Beauty Health (SKIN), Monogram Orthopaedics (MGRM), CapsoVision (CV), Sight Sciences (SGHT), Inogen (INGN), Profound Medical (PROF), KORU Medical Systems (KRMD), and TriSalus Life Sciences (TLSI). Inovio Pharmaceuticals vs. Its Competitors Moderna CVRx Beauty Health Monogram Orthopaedics CapsoVision Sight Sciences Inogen Profound Medical KORU Medical Systems TriSalus Life Sciences Inovio Pharmaceuticals (NASDAQ:INO) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings. Which has more volatility & risk, INO or MRNA? Inovio Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Do analysts rate INO or MRNA? Inovio Pharmaceuticals presently has a consensus price target of $8.80, suggesting a potential upside of 524.11%. Moderna has a consensus price target of $43.59, suggesting a potential upside of 66.88%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Inovio Pharmaceuticals is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Do insiders and institutionals hold more shares of INO or MRNA? 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 2.3% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 11.0% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to INO or MRNA? In the previous week, Moderna had 31 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 35 mentions for Moderna and 4 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 0.47 beat Moderna's score of 0.10 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 8 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher earnings and valuation, INO or MRNA? Inovio Pharmaceuticals has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInovio Pharmaceuticals$220K235.02-$107.25M-$3.19-0.44Moderna$3.24B3.14-$3.56B-$7.53-3.47 Is INO or MRNA more profitable? Inovio Pharmaceuticals has a net margin of 0.00% compared to Moderna's net margin of -94.31%. Moderna's return on equity of -25.96% beat Inovio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Inovio PharmaceuticalsN/A -136.93% -89.99% Moderna -94.31%-25.96%-20.09% SummaryInovio Pharmaceuticals and Moderna tied by winning 8 of the 16 factors compared between the two stocks. Get Inovio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INO vs. The Competition Export to ExcelMetricInovio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.71M$2.99B$5.50B$9.72BDividend YieldN/A2.28%4.59%4.12%P/E Ratio-0.4417.1130.0524.70Price / Sales235.02330.47456.53100.55Price / CashN/A40.7324.8428.01Price / Book0.748.888.525.76Net Income-$107.25M-$54.75M$3.27B$267.05M7 Day Performance-1.40%0.01%6.13%5.08%1 Month Performance1.44%0.64%0.07%0.61%1 Year Performance-83.29%8.71%36.43%22.83% Inovio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INOInovio Pharmaceuticals3.6556 of 5 stars$1.41-2.1%$8.80+524.1%-83.3%$51.71M$220K-0.44320Upcoming EarningsMRNAModerna4.4694 of 5 stars$27.64+0.1%$45.61+65.0%-69.2%$10.68B$3.24B-3.675,800Earnings ReportAnalyst RevisionCVRXCVRx2.8643 of 5 stars$7.55-0.1%$14.50+92.1%-15.2%$197.11M$51.29M-3.46160News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionSKINBeauty Health1.7429 of 5 stars$1.60+4.6%$2.08+30.2%+68.8%$192.77M$334.30M-3.901,030Trending NewsEarnings ReportAnalyst UpgradeGap UpMGRMMonogram Orthopaedics1.6714 of 5 stars$5.47+1.5%$5.40-1.3%+110.9%$192.36M$370K0.0028Upcoming EarningsCVCapsoVisionN/A$4.10+4.9%$5.50+34.1%N/A$181.21MN/A0.0090Quiet Period ExpirationSGHTSight Sciences1.8537 of 5 stars$3.47+6.1%$3.93+13.4%-28.9%$169.04M$79.87M-3.54210News CoverageEarnings ReportAnalyst UpgradeGap UpINGNInogen4.1917 of 5 stars$6.54+5.3%$11.00+68.2%-47.4%$166.97M$335.70M-5.691,030News CoveragePositive NewsEarnings ReportPROFProfound Medical1.7911 of 5 stars$5.64+2.5%$11.00+95.2%-40.7%$165.29M$10.68M-4.62150News CoverageKRMDKORU Medical Systems2.0715 of 5 stars$3.38-2.9%$4.63+36.8%+55.9%$160.57M$33.65M-30.7380News CoverageEarnings ReportTLSITriSalus Life Sciences2.0108 of 5 stars$4.20+0.5%$10.75+156.0%-30.2%$158.17M$29.43M0.00106Upcoming Earnings Related Companies and Tools Related Companies Moderna Alternatives CVRx Alternatives Beauty Health Alternatives Monogram Orthopaedics Alternatives CapsoVision Alternatives Sight Sciences Alternatives Inogen Alternatives Profound Medical Alternatives KORU Medical Systems Alternatives TriSalus Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INO) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inovio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INO Stock Alerts